+Vote!
Medical News Today (Free subscription) | 09/15/2008
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the malignant melanoma drug market, driven by the launch of emerging agents, will experience robust annual 12 percent growth through 2012 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
+Vote!
24/7 Wall St. (Free subscription) | 09/15/2008
There is some very hopeful data out there this morning in the land of cancer survival. Bristol-Myers Squibb Co. (NYSE: BMY) and Medarex, Inc. (NASDAQ: MEDX)... [[ This is a content summary only. Visit my website for full links, other content, and more! ]]
2Vote!
Medical News Today (Free subscription) | 09/05/2008
Medarex, Inc. (Nasdaq: MEDX) announced that nine clinical abstracts for ipilimumab, an investigational anti-CTLA-4 antibody, in melanoma are scheduled to be the subject of presentations at the 33rd Congress of the European Society for Medical Oncology (ESMO) being held September 12-16, 2008 in Stockholm.
+Vote!
PR News Wire (Free subscription) | 09/02/2008
PRINCETON, N.J., Sept. 2 /PRNewswire-FirstCall/ -- Medarex, Inc.
(Nasdaq: ) announced today that it is scheduled to present at the
Thomas Weisel Partners Healthcare Conference at 9:10 a.m. Eastern Time on
Thursday, September 4, 2008. The event will be webcast live and will be
available in the Investor Relations section of the Medarex website at
. An archived edition of the presentation will be available
following...
1Vote!
Medical News Today (Free subscription) | 08/13/2008
Medarex, Inc. (Nasdaq: MEDX) announced that its partner MedImmune, Inc. has initiated a Phase 2A multi-dose clinical trial of MEDI-545 for the potential treatment of systemic lupus erythematosus (SLE or lupus). MEDI-545 is a fully human antibody generated by Medarex's UltiMAb Human Antibody Development System(R).
+Vote!
PR News Wire (Free subscription) | 08/12/2008
Medarex to Receive Milestone Payment from MedImmune
PRINCETON, N.J., Aug. 12 /PRNewswire-FirstCall/ -- Medarex, Inc.
(Nasdaq: ) announced today that its partner MedImmune, Inc. has
initiated a Phase 2A multi-dose clinical trial of MEDI-545 for the
potential treatment of systemic lupus erythematosus (SLE or lupus).
MEDI-545 is a fully human antibody generated by Medarex's UltiMAb Human
Antibody Development...
1Vote!
Medical,Health News and Articles (Free subscription) | 08/06/2008
Medarex, Inc. (Nasdaq: MEDX) announced the allowance of an investigational new drug application (IND) filed with the U.S. Food & Drug Administration (FDA) for MDX-1105, for the treatment of patients with selected advanced or recurrent solid tumors, specifically renal cell carcinoma, melanoma, non-small cell lung cancer or epithelial ovarian cancer. MDX-1105 is a fully human [...]
1Vote!
PR News Wire (Free subscription) | 08/05/2008
PRINCETON, N.J., Aug. 5 /PRNewswire-FirstCall/ -- Medarex, Inc.
(Nasdaq: ) announced today its financial results for the quarter ended
June 30, 2008.
Medarex's net loss for the quarter ended June 30, 2008 was $53.1
million, or ($0.42) per share as compared to a net loss of $41.0 million,
or ($0.32) per share for the second quarter of 2007. Included in the 2008
results was a non-cash charge of $6.0...
+Vote!
Red Orbit (Free subscription) | 07/23/2008
PRINCETON, N.J., July 23 /PRNewswire-FirstCall/ -- Medarex, Inc. today announced that it has received a milestone payment of an undisclosed amount from its licensing partner, Centocor R&D Inc., for the acceptance of an Investigational New Drug Application (IND) to the U.S.
+Vote!
PR News Wire (Free subscription) | 07/23/2008
PRINCETON, N.J., July 23 /PRNewswire-FirstCall/ -- Medarex, Inc.
(Nasdaq: ) today announced that it has received a milestone payment of
an undisclosed amount from its licensing partner, Centocor R&D Inc., for
the acceptance of an Investigational New Drug Application (IND) to the U.S.
Food and Drug Administration (FDA) for an undisclosed antibody. The
antibody was generated by Medarex's UltiMAb Human...
+Vote!
PR News Wire (Free subscription) | 07/16/2008
PRINCETON, N.J., July 16 /PRNewswire-FirstCall/ -- BioWa, Inc. and
Medarex, Inc. (Nasdaq: ) announced today that they have entered into a
license agreement which provides Medarex with the first ever access to
BioWa's COMPLEGENT(TM) Technology for enhancing the complement-dependent
cytotoxicity (CDC) of select Medarex therapeutic antibodies.
The license grants Medarex non-exclusive rights to research,...
1Vote!
www.OSIR.org.in (Free subscription) | 07/10/2008
PRINCETON, N.J., July 10 /PRNewswire-FirstCall/ — Medarex, Inc. MEDX today provided a detailed overview of the company’s strategy, strength in research discovery and antibody development, and the multiple opportunities Medarex is engaged in for Source: news.moneycentral.msn.com Jodrell Bank radiotelescope spared the axe - ZDNet UKThe iconic radiotelescope at the Jodrell Bank Centre for Astrophysics,...
+Vote!
PR News Wire (Free subscription) | 07/10/2008
PRINCETON, N.J., July 10 /PRNewswire-FirstCall/ -- Medarex, Inc.
(Nasdaq: ) today provided a detailed overview of the company's
strategy, strength in research discovery and antibody development, and the
multiple opportunities Medarex is engaged in for creating long-term value.
In addition, comprehensive updates on current and future antibody programs
as well as updated 2008 financial guidance were...
+Vote!
The Street (Free subscription) | 07/10/2008
Why telaprevir dosing is key for Vertex; where in the world is Medarex CEO Howard Pien; what updates to look for in biotech earnings; and more.
